TransCode Therapeutics (RNAZ)
(Delayed Data from NSDQ)
$0.86 USD
-0.01 (-1.49%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.86 0.00 (0.35%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RNAZ 0.86 -0.01(-1.49%)
Will RNAZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RNAZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAZ
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
TransCode (RNAZ) Down 50% on Issue of New Common Stock
RNAZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for RNAZ
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics regains compliance with Nasdaq
Transcode Therapeutics regains compliance with Nasdaq listing requirements